• Home
  • About
  • Contact
  • Privacy
  • DCMA
  • Terms
  • Sitemap
  • Submit
Oscar Times
  • Home
  • Celebrity
  • Entertainment
  • Fashion
  • Fitness
  • Health
No Result
View All Result
Oscar Times
  • Home
  • Celebrity
  • Entertainment
  • Fashion
  • Fitness
  • Health
No Result
View All Result
Oscar Times
No Result
View All Result
Home Health

AI-powered eye screening platform Eyenuk raises $25M

October 17, 2022
Reading Time: 2 mins read
0
AI-powered eye screening platform Eyenuk raises $25M
Share on FacebookShare on TwitterShare on LinkedinShare on PinterestShare on Reddit

Eyenuk received $25 million in Series A funding to expand access to its AI-powered eye-screening technology that enables autonomous detection of diabetic retinopathy (DR) during a patient’s regular exam.

The recent raise was led by AXA IM Alts and joined by new and existing investors, including A&C Foelsgaard Alternativer ApS, T&W Medical A/S, KOFA Healthcare and Kendall Capital Partners. It brings the company’s total funding to $43 million.

RELATED STORIES

mug of coffee on table against the sunrise

Mark Sisson’s Early Morning Routine

November 17, 2022
Narcissists and Housework: Issues You May Run Into

Narcissists and Housework: Issues You May Run Into

November 16, 2022

The Series A raise includes approximately $6.2 million previously raised in convertible notes converted to Series A securities.

WHAT IT DOES

The company’s EyeArt AI software, which received 510(k) clearance from the FDA in 2020, allows for autonomous DR screening, including retinal imaging, DR detection and immediate reporting during a patient’s regular examination. After the patient’s fundus images are captured and submitted to EyeArt, results are provided via a PDF report in less than 30 seconds.

The announcement follows a study published in September in Ophthalmology Science where researchers compared general ophthalmologists, Eyenuk’s EyeArt Artificial Intelligence (AI) system and retina specialists for detecting more than mild DR (mtmDR). Results showed the AI system had higher sensitivity for detecting mtmDR than general ophthalmologists or retina specialists. 

Eyenuk will use the recently garnered Series A funds to expand its AI product platform with additional disease indications and accelerate the company’s global commercialization. 

MARKET SNAPSHOT

In August, AI-enabled diagnostics company Digital Diagnostics, formerly IDx, which also offers an AI-backed eye care system to detect diabetic retinopathy, announced it scored $75 million in a Series B funding.

Its IDx-DR system detects diabetic retinopathy, which can cause vision loss and blindness in people with diabetes. The IDx-DR product received FDA De Novo clearance in 2018. 

Google has also been exploring using AI for diagnostics in developing its product for detecting diabetic retinopathy called Automated Retinal Disease Assessment (ARDA). In March, the tech giant provided updates on its healthcare tools, noting it would continue research on ARDA to determine whether photos of the outside of the eye could detect disorders.

Source by www.mobihealthnews.com

Please login to join discussion

Trending Topics

  • How to Style Pakistani Wedding Maxi Dresses Like a Fashion Icon
  • The Finishing Touch: Mastering the Art of Accessorizing for Every Occasion
  • Stylists recommend checking out the top 7 summer fashion trends available on Amazon
  • What Materials Can Be Tested in Salt Spray Chambers?
  • Paid Toilet Management Optimization Hygiene and Security Focus
  • Ensuring Secure Connectivity for Employees through SOC 2 Compliance
  • How to Layer Skincare Products Correctly?
Oscar Times

© 2025 Oscartimes.com

Navigate Site

  • Home
  • About
  • Contact
  • Privacy
  • DCMA
  • Terms
  • Sitemap
  • Submit

Follow Us

No Result
View All Result
  • Home
    • Home – Layout 1
    • Home – Layout 2
    • Home – Layout 3
  • Landing Page
  • Buy JNews
  • Support Forum
  • Pre-sale Question
  • Contact Us